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This paper aims at analysing the main features of R&D activities carried out by the 
Italian biotech companies. The proposed contribution can be ascribed to the massive 
stream of research related to the reconfiguration of the value chain activities at the 
international level. Such a topic has become more and more actual because of both the 
markets globalisation and diffusion of networked architectures within internationalised 
companies (see, among others, Bartlett 1986; Bartlett and Goshal 1987, 1990; Bartlett, 
Doz and Hedlund 1990; Forsgren 1993; Forsgren and Holm 1993; Forsgren, Holm and 
Johanson 1991, 1992; Forsgren and Johanson 1992; Forsgren and Pedersen 1998; 
Hedlund  1979,  1980,  1986,  1994;  Hedlund  and  Ridderstrale  1994;  Hedlund  and 
Rolander 1990; Lipparini and Fratocchi 1999). Within such a stream of research, we 
decided to focus the attention on the biotech industry, due to its specific features, that 
deeply influence both the strategic behaviour of firms and the economic environment of 
the countries where they operate. 
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Keeping in mind the different types of biotech firms operating at global level, we have 
decided  to  focus  our  attention  to  a  less  heterogeneous  population.  In so  doing,  we 
narrowed the analysis to the red biotech segment (that is health care biotech companies 
which develop drugs and diagnostics), because of its absolute predominance both in 
Italy  (73%  of  enterprises,  94%  of  total  revenue  and  86%  of  investments
1)  and  at 
worldwide level (51% of EU firms and 60% of USA ones
2). First of all we collected data 
for a sample of companies operating in the Italian red biotech industry. Particularly, we 
focused on R&D activities: we tried to quantify its extent, to understand where they are 
located (domestically or abroad) and the role played by alliances/cooperation with -in 
and -out the industry. More specifically, in order to reach the goals above described, 
attention was paid to the aptitude of the Italian country-system to attract investments 
from  abroad.  In  doing  so,  we  studied  separately  the  Italian  independent  firms  and 
MNCs. Analysing the peculiarities of how Italian independent firms and MNCs manage 
R&D  activities,  we  tried  to  find  out  the  existence  of  a  different  approach  to  R&D 
investments.  
The paper is structured in four main sections. In the first one, the main relevant features 
of biotech firms are discussed and the literature background presented. The second 
paragraph deals with sample and methodology description. In the third section, the 
main results regarding the analysis of R&D activities carried out by the red Italian 
biotech companies are presented. The conclusions complete the paper.  
 




The proposed contribution can be ascribed to the massive stream of research related to 
the reconfiguration of the value chain activities at the international level. Such a topic 
has  become  more  and  more  actual  because  of  both  the  markets  globalisation  and 
diffusion of networked  architectures  within internationalised companies (see,  among 
others, Bartlett 1986; Bartlett and Goshal 1987, 1990; Bartlett, Doz and Hedlund 1990; 
Forsgren 1993; Forsgren and Holm 1993; Forsgren, Holm and Johanson 1991, 1992; 
Forsgren and Johanson 1992; Forsgren and Pedersen 1998; Hedlund 1979, 1980, 1986, 
1994;  Hedlund  and  Ridderstrale  1994;  Hedlund  and  Rolander  1990;  Lipparini  and 
Fratocchi 1999). 
Within such a stream of research, we decided to focus the attention on the biotech 
industry, due to its specific features, that deeply influence both the strategic behaviour 
of firms and the economic environment of the countries where they operate. 
First of all, the investigated sector is characterized by a high content of technological 
innovation (being R&D expenditure generally more than 30% of total sales). With this 
respect,  the  recent  study  of  Hopkins  et  al.  (2007),  according  to  which  the  biotech 
revolution would be simply a “myth”, seems to be a little exaggerated in its conclusions, 
since it does not consider the huge amount of research projects actually still in their 
development earlier stages. The high-tech nature of the investigated industry, in turn, 
leads  to  a  competition  essentially  based  on  “intensive  knowledge”  (Pavitt  1984). 
Consequently, enterprises definitively benefit of particularly qualified human resources 
that strictly depend on a high level university system. With this respect, JunKunc (2007) 
had recently demonstrated that the radical increase of the importance of specialized 4 
 
knowledge  in  such  an  industry  dramatically  impacts  on  the  possibility  to  include 
secondary shares in biotech-related IPOs. 
Moreover,  (public  and  private)  research  centres  and  health  care  providers  represent 
strategic  partners  as  well.  As  a  consequence,  co-localisation  and  agglomeration  in 
geographical clusters (such as the Cambridge area, Bio-Vallée, and Medicon Valley) 
typically characterize the biotech industry (see, among others, Mytelka and Farinelli 
2000). With this respect, Chiaroni and Chiesa (2006) recently proposed a taxonomy of 
biotech clusters based on how they have emerged. More specifically, they describe three 
main typologies: 
-  spontaneous  clusters,  which  emerge  from  the  concentration  of  specific 
conditions  (e.g.,  the  presence  of  an  excellent  scientific  base  and/or  of  an 
entrepreneurial culture), such as in the case of Cambridge area; 
-  policy-driven clusters, which directly originate from policy makers action: with 
this  respect,  authors  make  a  distinction  among  policies  related  to  an 
industry/firm restructuring (such as in the case of Uppsala, in Sweden) and those 
specifically devoted to the biotech development (such as in the case of France or 
Germany). With this respect, it is worth noting that the relevance of “national 
systems”  for  the  integration  of  technological  progress  with  public  interest  is 
largely recognized, since, at least, Bartolomew (1997); 
-  hybrid clusters, such as in the case of Milan (Italy) and San Diego (USA).   
Focusing  on  the  localisation  of  R&D  activities  carried  out  by  biotech  companies  a 
recent study of Jommi and Paruzzolo (2007) pointed out that the existing literature has 
not  yet  provided  a  complete  analysis  of  all  variables  potentially  influencing  the 
localisation of R&D in the pharmaceutical and biotech industries and that, in particular, 5 
 
so far there is no evidence on the Italian case-study. Another recent study provided, 
instead,  evidences  about  the  determinants  of  the  foreign  location  of  technological 
activities of MNCs (Le Bas and Sierra 2002) finding out that very often such companies 
locate their activities abroad in technological areas or fields where they are strong at 
home  or  seek  out  locations  that  have  complementary  strengths  to  their  own. 
Furthermore, Singh (2008) recently analysed the impact of geographic dispersion of a 
firm‟s R&D activities on the quality of its innovative output concluding that having 
geographically  distributed  R&D  per  se  does  not  improve  the  quality  of  a  firm‟s 
innovations being negatively associated with average value of innovations. According 
to Belderbos et al. (2005) managerial decisions related to localisation of R&D activities 
are influenced by local markets size, by local country per capita income, by abundance 
of  scientists  and  by  engineers  and  Intellectual  Property  Rights  regime  strength. 
Summarizing, the above quoted study of Jommi and Paruzzolo (2007) also provides a 
general framework on factors influencing localisation of R&D on pharmaceutical and 
biotech industry. These factors were classified into the following categories: regulatory 
environment, institutional framework, national system of innovation, local development 
and specialisation. 
Another characterizing element of biotech firms is the “metasectorial” nature of such 
business,  emerging  from  the  convergence  of  differentiated  industries,  such  as 
pharmaceutics, chemicals (and more specifically the combinatory one), Information and 
Communication Technology (as clearly showed by the so-called platform companies), 
human and veterinary medicine, food processing. This convergent nature implies the 
simultaneous presence in the sector of very differentiated economic players, coming 
from different competitive fields. At the same time, biotechnology platforms can be 6 
 
applied in different market contexts; with this respect, it is generally accepted the idea 
to  classify  biotech  firms  along  the  following  segments:  “red/health  care” 
(pharmaceutical  and  diagnostic  business),  “green”  (agriculture,  zootechnics  and 
veterinary  medicine),  “white/grey”  (industrial  and  environmental  field)  and 
“platform/bioinformatics”. 
Due to dispersion of such various sources of knowledge and application fields all over 
the world, biotech firms are diffused in several territorial contexts. This because the 
knowledge necessary for the construction of a sustainable competitive advantage are 
scattered  in  a  plethora  of  geographic  areas  (Cookson  2005),  which  need  to  be 
contemporarily garrisoned (the so called “meta-national” business approach quoted by 
Doz, Santos and Williamson 2002). Those evidences explicitly induce to adopt new 
theoretical frameworks to investigate such a business. With this respect, Madhok and 
Osegowitsch (2000) proposed the adoption of a dynamic capabilities and technology 
accumulation perspective for investigating the biotech industry. More recently Mathews 
and  Zander  (2007)  advanced  the  idea  of  linking  the  internationalisation  and 
entrepreneurial perspectives.  
The  biotech  industry  is  often  described  as  being  composed  of  different  industrial 
organization often labelled as “non-self sufficient” and “non-autonomous” companies 
under the strategic point of view (Phillips and Beckman 2001; Onetti and Zucchella 
2008)  that  set  up  complex  collaborative  arrangements/relationships  networks 
established with other companies (Powell and Brantley 1992) or institutions (Pisano 
2006).  The  relational  dimension  in  this  industry  is  very  important  because  value 
creation  is  mainly  based  on  R&D  activity  that  relies  on  research,  financial  and 
institutional partnerships. In fact, on the one hand, knowledge creation pass through 7 
 
“networks  for  exploration”  and  on  the  other  hand,  the  exploitation  of  generated 
knowledge  and  research  products  commercialization  is  based  on  commercial 
partnerships/agreements  with,  for  example,  big  pharmaceutical  companies.  The  last 
relationships described form the so called “networks for exploitation” (March 1991; 
Rothermael  and  Deeds  2004).  The  biotech  industry  is  recognised  as  being  a 
paradigmatic  case  of  “distributed  innovation”,  since  R&D  activity  is  based  on 
interorganizational and interpersonal partnerships (Onetti and Zucchella 2008) that, as 
example for the red biotech segment, involve big pharmaceutical companies, research 
institutions, hospitals and universities (Hagedoorn 1993; Oliver 2004; Lim, Garnsey and 
Gregory 2006; Powell, Koput and Smith-Doerr 1996; Owen-Smith and Powell 2004, 
Stuart, Ozdemirb and Ding 2007; Gilsing and Noteboom 2006). 
On  the  basis  of  what  previously  discussed,  and  given  the  importance  of  research 
partnerships  in  the  biotech  field  (Powell  et  al.  1996;  Cunningham  2002;  Audretsch 
2001; Audretsch and Feldman 2003; Chiesa 2003; Pisano 2006; Miles et al. 2006), we 
decided  to  focus  our  attention  on  R&D  activity  carried  out  by  Italian  red  biotech 
companies trying to quantify its extent, to understand where they are located and the 
role played by cooperation with -in and -out the industry. 
2. DATA AND METHODOLOGY 
On the basis of the theoretical framework previously described, we focused the analysis 
on the red biotech segment, because of its absolute predominance both in Italy (73% of 
enterprises, 94% of total revenue and 86% of investments) and at worldwide level (51% 
of EU firms and 60% of USA ones).  
We referred to Blossom Associati-Assobiotec 2006 and 2007 Report for the data and 
the segmentation criteria of Italian biotech sector. In order to specifically investigate the 8 
 
main features of R&D activities, companies performing exclusively sales activities were 
excluded. We thus identified 162 red biotech companies and sent them a questionnaire 
in order to collect both qualitative and quantitative data. The questionnaire was made up 
of the following sections: 
General information: location(s) in Italy, eventual listing at stock markets, country of origin (only for 
subsidiaries) 
Managed activities: research and development, clinic development, production, and sales 
Collaborations  with  selected  actors:  university  and  other  research  centres,  multinational  firms, 
incubators and scientific parks, hospitals and clinics 
Economic  and  financial  data:  total  number  of  employees  (at  world  level  and  in  Italy  for 
multinationals), total amount of revenue (at world level and in Italy for multinationals), percentage of 
people devoted to R&D; percentage of revenue arising from biotech technologies/processes; amount of 
investments in research and development (at world level and in Italy for multinational), percentage of 
such investments in biotech technologies/processes 
Therapeutic areas of specialization 
Number of products/projects in the different stage of the pipeline 
Number of processes developed in Italy 
 
The  data  collected  through  questionnaires  were  integrated  with  annual  reports  and 
records from Chamber of Commerce. The survey was conducted between 2006 and 
2007. 
We received 43 fully compiled questionnaires obtaining an answer rate of about 26.5%, 
which can be considered a satisfactory results if compared to figures obtained by the 
best international surveys (Harzing 1997). The most relevant features of the investigated 
sample are summarized in tables 1 and 2.  
In our survey we decided to carry out, on the sample of 43 red biotech companies 
localised  in  Italy  a  qualitative  analysis  through  which  we  get  evidences  about  the 9 
 
investigated  phenomenon.  In  order  to  do  that,  companies  were  further  divided 
accordingly  to  the  governance  structure  in  Italian  independent  firms  and  in 
multinational companies. The latter were divided in Italian MNCs and in subsidiaries of 
foreign MNCs. To identify the main features of the R&D activities performed by the 
investigated firms this paper mainly addresses the following research questions: 
-  How is R&D activity managed by Italian independent firms and by MNCs? 
-  Does company localization affect the localization of R&D activity? Is there any 
difference between Italian independent firms and MNCs? 
-  Do  Italian  independent  firms  and  MNCs  present  a  different  attitude  towards 
research partnership development? 
3. RESULTS DISCUSSION 
First of all, it is worth noting the main features of the respondents. In doing so, we draw 
our attention to the governance structure and find out that nearly 60% of the sample is 
composed of Italian independent firms and 40% of multinational companies (the latter 
are formed of 20% of Italian MNCs and 80% of subsidiaries of foreign MNCs). 
Under the point of view of the corporate model adopted by the red biotech companies, 
our sample is composed by nearly 40% of “born biotech” and by 60% of “pharma 
biotech” companies (see table 1). Born biotech are companies whose core business is 
mainly  oriented  to  research  and  development  activities,  while  pharma  biotech,  also 
called “diversified companies”, are mainly pharmaceutical firms that diversify in the 
biotechnological  sector  or  biotechnological  companies  deriving  from  the 
pharmaceutical industry; they are therefore companies operating along the entire value 
chain of the pharmaceutical sector. 
 10 
 






Born biotech 56.0% 20.0% 15.4% 16.7% 39.5%
Pharma biotech 44.0% 80.0% 84.6% 83.3% 60.5%






Source: own calculations on data Blossom Associati – CrESIT, 2006 
According to company size, we can notice that nearly half of our sample is composed 
by small sized companies, 35% of large companies and the rest are medium firms (see 
table 2). It is worth noting that nearly 90% of all small sized companies are Italian 
independent firm and more than 50% of large companies are subsidiaries of foreign 
MNCs. 






Large 16.0% 60.0% 61.5% 61.1% 34.9%
Medium 8.0% 40.0% 23.1% 27.8% 16.3%
Small 76.0% 0.0% 15.4% 11.1% 48.8%






Source: own calculations on data Blossom Associati – CrESIT, 2006 
Notes:   to investigate the distribution of respondents firms according to size,  we referred to the EU 
definitions introduced by the Recommendation 361/2003 
As regards geographical distribution, one can notice that companies of the sample are 
generally concentrated in a selected number of clusters (see table 3). More specifically, 
more than 80% of red biotech companies are located only in three regions: Lombardy in 
the North, Tuscany and Latium in the Centre.  
Lombardy is the area with the higher concentration of biotech companies (Orsenigo 
2001; Chiesa 2003; OECD 2006; Blossom Associati-Assobiotec 2006, 2007; Onetti and 
Zucchella 2008; Pisoni 2008; Castaldi 2009). Companies are mainly concentrated in the 11 
 
area  of  Milan  where  the  main  Italian  research  centres  are  located  (IPI  2007).  As 
expected,  in  this  area  we  found  the  higher  concentration  both  of  born  biotech  and 
pharma biotech (with a slight prevalence of born biotech) and of Italian independent 
firms and MNCs (with a slight prevalence of Italian independent firms). 
On  the  contrary,  Latium  is  featured  by  a  stronger  presence  of  MNCs  of  large 
pharmaceutical companies, more oriented to manufacturing and sales activities than to 
R&D. In Rome and Latina, for instance, we found a high percentage of pharma biotech 
companies (nearly 23% of the total sample). This result may be explained by the huge 
presence,  in  such  two  areas,  of  pharmaceutical  companies,  especially  large 
multinationals (we refer, among others, to Pfizer, Merck Sharp & Dohme, Bristol Myers 
Squibb). This presence arises from the proximity to Rome and the availability of fiscal 
incentives and grants in those areas, which were considered less developed until the 
beginning of „90s. Finally, Tuscany, were is located nearly the 16% of all MNCs of the 
sample, show a slight dominance of born biotech companies (23.5% of the total versus 
15.4%  of  pharma  biotech  ones).  In  this  region  we  find  out  two  big  multinational 
companies  (Chiron,  Grifols)  that  started  their  activities  in  the  early  nineties.  Is  our 
opinion that this could have boosted in that region the trend to invest in R&D.  
If we analyse data at a district level, two main clusters emerge: Milan
3 (where is located 
50% of all MNCs and 53% of total pharma biotech) and Rome (where is located 11% of 
all MNCs and 15% of total pharma biotech). In Tuscany, there is a more fragmented 
situation being MNCs and pharma biotech companies almost equally distributed in three 
local districts: Pisa, Siena, and Florence. Being them quite close each other, it may be 
assumed they belong to the same cluster, often referred (Blossom Associati - Assobiotec 
2006)  as  the  “Tuscan  biotech  cluster”.  Based  on  such  assumptions,  we  noted  that 12 
 
pharma biotech companies are all large corporations, since they are mainly subsidiaries 
of foreign multinational companies (see tables 1 and 2).  








Lombardy Milan 40% 40.0% 53.8% 50.0% 44.2%
Monza 20.0% 5.6% 2.3%
Lodi 4.0% 2.3%
Varese 4.0% 2.3%
Latium Rome 8.0% 20.0% 7.7% 11.1% 9.3%
Latina 15.4% 11.1% 4.7%
Pisa 4.0% 7.7% 5.6% 4.7%
Tuscany Siena 8.0% 7.7% 5.6% 7.0%
Florence 4.0% 20.0% 5.6% 4.7%
Livorno 4.0% 2.3%
Piedmont Torino 4.0% 2.3%
Ivrea 4.0% 2.3%
Veneto Venice 4.0% 2.3%
Friuli Venezia Giulia Gorizia 4.0% 2.3%
Campania Naples 4.0% 2.3%
Sardinia Cagliari 4.0% 7.7% 5.6% 4.7%








Source: own calculations on data Blossom Associati – CrESIT, 2006 
Analysing the firms‟ value chain, we noted that R&D activities are mainly located (51% 
of all R&D activities) in the same region where is also located the company‟s registered 
office (see table 4). Moreover, data show that nearly 23% of all R&D activities are 
performed in more than one location. Further insights show that Italian independent 
firms, among the others, followed by Italian MNCs are the one that select more than one 
location to establish R&D activities. It is worth noting that, unfortunately, about 70% of 
foreign MNCs do not declare the exact location of R&D activity in Italy.  13 
 







Lombardy in the same region 32.0% 40.0% 11.1% 23.3%
in other region
multi location 16.0% 20.0% 5.6% 11.6%
Latium in the same region 4.0% 7.7% 5.6% 4.7%
in other region 7.7% 5.6% 2.3%
multi location 4.0% 20.0% 5.6% 4.7%
Tuscany in the same region 12.0% 7.7% 5.6% 9.3%
in other region
multi location 4.0% 20.0% 5.6% 4.7%
Piedmont in the same region 8.0% 4.7%
in other region
multi location
Veneto in the same region 4.0% 2.3%
in other region
multi location
in the same region
in other region
multi location 4.0% 2.3%
Campania in the same region 4.0% 2.3%
in other region
multi location
Sardinia in the same region 4.0% 7.7% 5.6% 4.7%
in other region
multi location
Total in the same region 68.0% 40.0% 23.1% 27.8% 51.2%
in other region 7.7% 5.6% 2.3%
multi location 28.0% 60.0% 16.7% 23.3%
ND 4.0% 69.2% 50.0%












Source: own calculations on data Blossom Associati – CrESIT, 2006 
Thus  seems  to  confirm  the  idea  that,  due  to  dispersion  of  the  various  sources  of 
knowledge  and  application  fields  all  over  the  world,  biotech  firms  are  diffused  in 
several  territorial  contexts.  Moreover,  data  shows  that  R&D  activities  seem  to  be 
polarized in the same areas of major concentration of biotech firms. Thus seems to 
confirm  the  idea  that,  in  order  to  access  specific  knowledge,  healthcare  biotech 
companies could take advantage of geographical proximity to clustered location (see 
among the others, van Geenhuizen and Reyes-Gonzalez 2007). 
Considering data in table 5, regarding the percentage of employees involved in R&D 
(on the total number of employees), as a proxy of R&D investments we can notice how 14 
 
Italian independent firms‟ investment efforts in R&D activity/projects seem to be higher 
in comparison to what arises from MNCs. In fact, nearly 60% of Italian independent 
firms has at least half of their employees involved in R&D activities against about 20% 
of MNCs.  









Up to 5% 7.7% 5.6% 2.3%
From 5.1% to 10% 8.0% 38.5% 27.8% 16.3%
From 10.1% to 15% 8.0% 20.0% 7.7% 11.1% 9.3%
From 15.1 to 20% 4.0% 20.0% 7.7% 11.1% 7.0%
From 20.1 % to 25% 20.0% 7.7% 11.1% 4.7%
From 25.1% to 50% 20.0% 20.0% 7.7% 11.1% 16.3%
From 50.1% to 75% 20.0% 11.6%
More than 75% 40.0% 20.0% 7.7% 11.1% 27.9%
ND 15.4% 11.1% 4.7%







Source: own calculations on data Blossom Associati – CrESIT, 2006 
Moreover, being MNCs of our sample mainly subsidiaries of foreign pharmaceutical 
companies the collected data are perfectly aligned to the one of a recent report issued by 
PWC (2007) that point out the low investment efforts of such companies. Thus, in our 
opinion, confirms the lower value added orientation of the latter type of companies, 
which  seem  to  conceptualise  our  country  more  as  a  market  opportunity  than  a 
knowledge base to be exploited. In fact, from the literature about “R&D centralization 
vs. delocalisation” reviewed in the first section of the paper arises, among other factors, 
the importance of the national system of innovation in influencing the localisation of 
R&D activities. 
Finally our research focused on collaborations that biotech companies set up with other 
actors in- and outside the industry. As earlier explained, this is a widely recognized 15 
 
success factor in the biotech industry (see among the others: Koput, Powell and Smith-
Doerr  1996),  since  the  high  intensity  of  knowledge  required.  With  this  respect,  a 
primary relation is generally realised with universities (Stuart et al. 2007; Berkovitz and 
Feldman 2007); as a consequence we expect such collaborations to be a widespread 
phenomena, with no respect to the business model (born biotech or pharma biotech, size 
and “origin”). Data summarized in table 6 completely confirm such an hypothesis. In 
fact, as the table below show, most of the firms in the sample (almost 90%) are tightly 
connected with universities, a lot of them with research centres (72%) and hospitals 
(65%) and fewer with other multinational companies (50%) and with incubators (about 
30%) (see table 6).  









Universities Performed 92.0% 100.0% 69.2% 77.8% 86.0%
Non Performed 23.1% 16.7% 7.0%
ND 8.0% 7.7% 5.6% 7.0%
Total 100.0% 100.0% 100.0% 100.0% 100.0%
Research centres Performed 72.0% 80.0% 69.2% 72.2% 72.1%
Non Performed 4.0% 20.0% 23.1% 22.2% 11.6%
ND 24.0% 7.7% 5.6% 16.3%
Total 100.0% 100.0% 100.0% 100.0% 100.0%
MNCs Performed 60.0% 80.0% 15.4% 33.3% 48.8%
Non Performed 16.0% 20.0% 69.2% 55.6% 32.6%
ND 24.0% 15.4% 11.1% 18.6%
Total 100.0% 100.0% 100.0% 100.0% 100.0%
Incubators Performed 36.0% 40.0% 15.4% 22.2% 30.2%
Non Performed 32.0% 60.0% 69.2% 66.7% 46.5%
ND 32.0% 15.4% 11.1% 23.3%
Total 100.0% 100.0% 100.0% 100.0% 100.0%
Hospitals Performed 60.0% 80.0% 69.2% 72.2% 65.1%
Non Performed 12.0% 20.0% 23.1% 22.2% 16.3%
ND 28.0% 7.7% 5.6% 18.6%







Source: own calculations on data Blossom Associati – CrESIT, 2006 
Some evidences arising from the table need to be clarified. First of all, as regards the 
collaboration with MNCs, it is logically expected that such relationships will take place 16 
 
only  for  companies  established  in  Italy,  since  such  a  type  of  collaboration  maybe 
defined  for  foreign  subsidiaries  at  headquarters  level.  Thus  could  explain  the  low 
percentage of subsidiaries of foreign MNCs that declare to perform it. Secondly, it is 
worth noting that the partnerships with incubators seem to be less important. However, 
such a result could have been affected by the limited presence of incubators in our 
country. As a consequence, these relationships are not very diffused, especially among 
MNCs. 
In analysing all the research relationships established by the companies under study, we 
would like to focus on the ones that have been developed with universities because of 
several factors. First of all, scholars agree on their importance in establishing networks 
of  knowledge  exploration  (see  among  the  others,  Stuart  et  al.  2007;  Berkovitz  and 
Feldman 2007; Onetti and Zucchella 2008), moreover in our sample they seem to be the 
most articulated and show the highest degree of response.  
Table7. Number of collaborations performed by red biotech companies with universities 
Collaboration with universities
NR (%) NR (%) NR (%) NR (%) NR (%)
of the same district 2 4.7% 2 22.2% 4 23.5% 6 23.1% 8 11.6%
 of the same region 11 25.6% 2 22.2% 1 5.9% 3 11.5% 14 20.3%
of other Italian regions 15 34.9% 2 22.2% 10 58.8% 12 46.2% 27 39.1%
of other European countries 11 25.6% 1 5.9% 1 3.8% 12 17.4%
of Asian countries 1 2.3% 0 0.0% 1 1.4%
of US  3 7.0% 2 22.2% 2 7.7% 5 7.2%
of other countries in the world 1 11.1% 1 5.9% 2 7.7% 2 2.9%










Source: own calculations on data Blossom Associati – CrESIT, 2006 
Table  7  provides  a  picture  of  the  network  of  collaborations  between  red  biotech 
companies and universities. From the table, clearly arises how the emerging network of 
R&D collaborations is largely based on relationships established at national level, i.e. 
71% of all agreements are among actors within the national territory. In detail, 40% of 
Italian independent firms presents a strong national embeddedness (performing 57% of 17 
 
all relationships established with universities) if compared to the same attitude shown 
by Italian MNCs (only 8.7% of the total amount) and by subsidiaries of foreign MNCs 
(20%).  At  the  same  time,  data  provides  evidences  of  the  different  attitude  between 
Italian  independent  firms  and  MNCs  to  establish  an  international  network  of  R&D 
collaborations. In fact, further analyses demonstrate that the overwhelming majority of 
all  relationships  established  with  universities  (75%)  are  developed  by  Italian 
independent firms that therefore show a considerable interest in linking themselves to 
foreign universities. Being Italian independent firms mainly small companies (see table 
2) it appears not to be surprisingly that they perform the majority of the partnerships 
surveyed in this study. In fact, as Powell (1998) pointed out, knowledge exploitation for 
small  biotech  firms  relies  more  than  the  others  (medium  and  large  ones)  on  the 
existence of collaborative partnerships. 
CONCLUSIONS 
The paper aims at presenting the main features of R&D activities of the Italian red 
biotech industry. This industry was chosen because of the high uncertainty and complex 
knowledge base required that raise the importance of R&D activity as unquestionable. 
The analysis carried out on a sample of 43 red biotech companies identifies first of all a 
picture of the location of R&D activities in Italy. Moreover, the survey provides further 
insights on R&D collaborations performed. The final purpose of the paper is to identify 
different attitude, if any, in managing R&D activities between Italian independent firms 
and MNCs, both Italian and subsidiaries of foreign companies. 
First of all, it arises that red biotech companies are generally concentrated in a selected 
number of regional clusters, more specifically Lombardy, Tuscany and Latium. If we 
analyse data at a more specific level, two main clusters emerge: Milan (where is located 18 
 
more than 50% of total red biotech) and Rome (14%). Similar results were obtained in 
analysing  the  location  of  R&D  activities.  As  regards  R&D  investments  efforts 
performed by the red biotech companies analysed, we find out  a different approach 
between Italian independent firms and MNCs, especially foreign ones. In 2006, 60% of 
Italian  independent  companies  reserve  more  than  half  of  their  employees  to  R&D 
activities,  compared  to  the  11%  (altogether  considered)  of  the  multinational  ones. 
Considering such numbers it seems possible to argue that Italy seems to be considered 
by  multinationals  more  as  a  market  opportunity  rather  than  a  venue  for  R&D 
investments. In fact, being MNCs mainly subsidiary of pharma biotech companies, they 
are  more  focused  on  manufacturing  activities  since  they  are  typically  related  to 
pharmaceutical production.  
Moreover,  as  regards  R&D  activities,  we  also  find  out  a  certain  good  level  of 
collaboration with local actors, as hospitals and universities. That is a widely recognized 
success factor in the biotech industry (Koput, Powell and Smith-Doerr 1996), since the 
high-intensity  of  knowledge  required.  In  particular,  we  focused  on  relationships 
established by biotech companies with universities. Once again, we compare the attitude 
towards the establishment of R&D partnerships of Italian independent firms and MNCs. 
It arises the strong attitude of Italian independent firms to internationalize their research 
alliances network. This result is particularly relevant because of the small size of these 
companies that force them to build several R&D partnerships to encompass the lack of 
resources that characterize their business (Powell 1998).  
Concluding, our results show that the Italian general framework of factors influencing 
R&D  localisation  does  not  seem  to  be  able  to  influence  the  localisation  of  R&D 
activities of biotech MNCs. Therefore, under this point of view, the aptitude of the 19 
 
Italian country-system to attract investments from abroad seems to be particularly weak. 
With respect to such aspect, it is necessary to point out the unanimous belief - of both, 
researchers and policy makers - how foreign direct investments (particularly the high 
knowledge  and  innovation  based)  deeply  impact  on  the  economic  strength  and 
development  of  the  country  of  destination  (Findlay  1978;  Barrel  and  Pain  1997; 
Borenszeiten, De Gregorio and Lee 1998). However, it is necessary to remember the 
exploratory  nature  of  this  paper,  as  a  consequence  we  are  not  yet  able  to  provide 
comprehensive guidelines for decision makers. Further analysis on biotech industry will 




1 Data source is: BLOSSOM ASSOCIATI - ASSOBIOTEC, Biotechnology in Italy 2007. Financial and 
strategic analysis; Blossom Associati – Assobiotec Report, Milan, 2007 
2  Data  source  is:  Critical I,  Biotechnology  in  Europe:  2005  Comparative  study,  BioVision, 
Lyon, 2005. It is worth noting that such analysis includes also support and services firms to the 
biotech sector – which are not considered in our paper focused at the Italian level. This could 
partially affect the comparison. 
3 It is worthy to note that Monza is a new autonomous province but is geographically contiguous 
to Milan, so they may be considered a unique cluster. 20 
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